Your browser doesn't support javascript.
loading
Cardiovascular Dysfunction in Multiple Sclerosis.
Mincu, Raluca Ileana; Magda, Lucia Stefania; Florescu, Maria; Velcea, Andreea; Mihaila, Sorina; Mihalcea, Diana; Popescu, Bogdan O; Chiru, Adela; Tiu, Cristina; Cinteza, Mircea; Vinereanu, Dragos.
Afiliação
  • Mincu RI; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
  • Magda LS; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
  • Florescu M; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
  • Velcea A; Department of Cardiology, Emergency University Hospital, Bucharest, Romania.
  • Mihaila S; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
  • Mihalcea D; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
  • Popescu BO; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
  • Chiru A; Department of Neurology, Colentina Clinical Hospital, Bucharest, Romania.
  • Tiu C; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
  • Cinteza M; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
  • Vinereanu D; "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Maedica (Bucur) ; 10(4): 364-370, 2015 Sep.
Article em En | MEDLINE | ID: mdl-28465741
ABSTRACT
Multiple sclerosis (MS) is a chronic neurological condition, characterized by recurrent episodes of inflammation and demyelination of the central nervous system called relapsing-remitting episodes, and continuous axonal degeneration that leads to irreversible progressive invalidity. Patients with multiple sclerosis present a higher mortality rate compared to the general population, and the excess of mortality may be explained by the increased cardiovascular risk and occurrence of cardiovascular disease. However, the exact pathways to cardiovascular dysfunction are not yet completely elucidated. This review focuses on the most important mechanisms of cardiovascular dysfunction in MS, such as the cardiomyocite structure alteration, the cardiovascular autonomous nervous system dysfunction, physical invalidity, oxidative stress and endothelial dysfunction, as well as the impact of cardiovascular risk factors in MS. The latest evidence about therapeutic approaches for MS, such as immunomodulatory treatment, vitamin D supplementation and statins are also discussed. There is little knowledge about the cardiovascular dysfunction in MS, and further research is required to improve the understanding of these complex mechanisms.

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Ano de publicação: 2015 Tipo de documento: Article